Crossref
SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?
Value in Health · 2026-06 · 29 (6) · S441
DOI: 10.1016/j.jval.2026.03.2181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Tim Disher.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Disher, T. (2026). SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?. Value in Health, 29(6), S441. https://doi.org/10.1016/j.jval.2026.03.2181
Vancouver
Disher T. SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?. Value in Health. 2026;29(6):S441. doi:10.1016/j.jval.2026.03.2181
BibTeX
@article{Disher2026,
author = {Disher, Tim},
title = {SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S441},
doi = {10.1016/j.jval.2026.03.2181}
}
EUVIMED